Publication | Closed Access

Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML

Hematological MalignancyTransplantationMedicineHigh-risk Myelodysplastic SyndromeHematologyPharmacotherapyPretransplant ComorbiditiesOncologyMyeloid Neoplasia